

1. (Currently Amended) A kit of parts comprising two or more protein kinase substrate polypeptides, each said substrate polypeptide comprising a specificity conferring portion, ~~(which wherein the specificity conferring portion is different for each said kinase substrate polypeptide)~~, and a phosphorylatable portion, wherein the phosphorylatable portions portion of each said substrate polypeptide ~~are~~ is capable of being bound in a phosphorylation state-sensitive manner by ~~the same~~ a specific binding partner, ~~for example an antibody preparation,~~ and wherein ~~the~~ said specific binding partner is not an antibody specific for phosphotyrosine, phosphoserine or phosphothreonine.

2. (Original) The kit of claim 1 wherein the phosphorylatable portions of the polypeptides have identical amino acid sequences.

3. (Currently Amended) A kit of parts ~~comprising two or more polypeptides, wherein the polypeptides are two or more protein kinase substrate polypeptides as defined in claim 1 or 2 in which wherein~~ the phosphorylatable portion of at least one said polypeptide is phosphorylated.

4. (Currently amended) The kit of ~~any one of claims~~ claim 1 to 3 wherein each said polypeptide is of less than 40, 30, 20, 19, 18, 17, 16, 15, or 14 amino acids in length.

5. (Original) The kit of claim 4 wherein said polypeptide is 13, 12, 11, 10 or 9 amino acids in length.

6. (Currently Amended) The kit of ~~any of the preceding claims~~ claim 5 wherein the protein kinase substrate

polypeptide is a substrate for a serine/threonine protein kinase.

7. (Currently Amended) The kit of ~~any of the preceding claims~~ claim 1 wherein the phosphorylatable portion has the amino acid sequence LSFAEPM.

8. (Currently Amended) The kit of ~~any of the preceding claims~~ claim 1 further comprising the specific binding partner.

9. (Currently Amended) The kit of ~~any of the preceding claims~~ claim 8 wherein the specific binding partner is an antibody.

10. (Original) An antibody specific for the epitope formed by the amino acid sequence LSFAEPM.

11. (Original) An antibody specific for the epitope formed by the amino acid sequence LpSFAEPM.

12. (Original) A polypeptide of less than 40, 30, 20, 19, 18, 17, 16, 15, or 14 amino acids in length wherein the polypeptide is not a fragment of glycogen synthase kinase 3, and wherein the polypeptide comprises the amino acid sequence LSFAEPM (which includes sequences with no, one, two, three, four or five residues (other than serine) conservatively substituted) and further comprising a specificity conferring portion comprising an amino acid sequence (which may overlap with the sequence LSFAEPM) corresponding to a consensus sequence for a protein kinase, wherein the sequence corresponding to the consensus sequence is positioned relative to the sequence LSFAEPM such that the protein kinase is capable of phosphorylating the polypeptide at the serine

residue of the sequence LSFAEPG.

13. (Original) The polypeptide of claim 12 wherein the polypeptide is 13, 12, 11, 10, or 9 amino acids in length.

14. (Currently Amended) The polypeptide of claim 12 or 13 wherein the amino acid sequence corresponding to the consensus sequence extends to the N-terminus of the sequence LSFAEPG.

15. (Currently Amended) The polypeptide of ~~any one of claims 12 to 14~~ claim 12 wherein the consensus sequence is Arg/Lys-Arg/Lys-Arg/Lys-Xaa-Ser, Arg/Lys-Xaa-Arg/Lys-Xaa-Xaa-Ser, Hyd-Xaa-Arg-Xaa-Ser or Xaa-pSer-Xaa-Ser.

16. (Currently Amended) A polypeptide according to ~~any one of claims 12 to 15~~ claim 12 in which the serine in the sequence LSFAEPG is replaced by phosphoserine.

17. -18. Canceled

19. (Currently Amended) A method for screening for protein kinases in a sample which may contain protein kinases comprising exposing a polypeptide as defined in ~~any one of the preceding claims~~ claim 12 to the sample and determining whether and optionally to what extent ~~the~~ said polypeptide is phosphorylated.

20. (Currently Amended) A method for assaying the activity of a protein kinase, comprising the steps of exposing the protein kinase to a polypeptide according to ~~any one of claims~~ claim 12 to 15 and determining whether and optionally to what extent ~~the~~ said polypeptide is phosphorylated.

21. (Currently Amended) A method of assessing the activity of a first protein kinase and a second protein kinase, comprising the steps of exposing the first protein kinase to a first polypeptide of a kit according to claim 1, and exposing the second protein kinase to a second polypeptide of a kit according to claim 1; and determining whether and optionally to what extent ~~the~~ said polypeptide is phosphorylated.

22. (Currently Amended) A method for assessing the activity of a protein kinase, comprising the steps of exposing the protein kinase to a first (unphosphorylated) peptide of a kit of claim 2, and determining whether and optionally to what extent ~~the~~ said polypeptide is phosphorylated.

23. (Currently Amended) A method for characterising the substrate specificity of a protein kinase, comprising the steps of exposing the protein kinase to a first polypeptide of a kit of claim 1, and exposing the protein kinase to a second polypeptide of a kit of claim 1; and determining whether and optionally to what extent ~~the~~ said polypeptides are phosphorylated.

24. (New) The kit of parts according to claim 1 wherein said specific binding partner is an antibody.

25. (New) The kit of parts according to claim 1 wherein the specific binding partner for the phosphorylatable portion of each said substrate polypeptide is the same.

Respectfully submitted,

October 8, 2004

Date

Karla M. Weyand

Karla M. Weyand
Registration No. 40,223

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 716-626-5380
Fax: 716-626-5384